PFF shares late breaking news about investigational therapies for IPF. Boehringer Ingelheim Announces Nintedanib Expanded Access Program (EAP) for Patients with Idiopathic Pulmonary Fibrosis As the trusted resource for the pulmonary fibrosis community by raising awareness, providing disease education, and funding research, the Pulmonary Fibrosis Foundation shares this late breaking news. For further information about investigational therapies for IPF, watch the recorded PFF Disease Education Awareness webinar, Ask a Doc: Clinical Trial Update, with PFF experts discussing clinical trial results for pirfenidone, nintedanib and N-Acetylcysteine. Contact the PFF Patient Communication Center for further information, 844.TalkPFF (844.825.5733) and [email protected].
Posted on: Wed, 25 Jun 2014 00:16:03 +0000
Trending Topics
Recently Viewed Topics
© 2015